Ceribell CBLL 深 滬
已收盤 12-24 16:00:00 美东时间
21.42
+0.130
+0.61%
華盛通- 最 高21.65
- 今 開21.25
- 成交量 20.61万股
- 最 低 21.01
- 昨 收 21.29
- 總市值 7.95亿
- 52周最高 26.83
- 市盈率 靜 --
- 換手率 0.56%
- 52周最低 10.01
- 委 比 87.78%
- 總股本 3709.57万
- 歷史最高 32.7489
- 量 比 0.46
- 振 幅 3.01%
- 歷史最低 10.01
- 每 手 1
- 風險率 4.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
12-16 09:36
BTIG Reiterates Buy on CeriBell, Maintains $30 Price Target
BTIG analyst Marie Thibault reiterates CeriBell (NASDAQ:CBLL) with a Buy and maintains $30 price target.
12-15 18:39
Ceribell, Inc. Extends Sunnyvale Office Leases
Ceribell, Inc. ( ($CBLL) ) has provided an update. On December 11, 2025, Ceribe...
12-13 02:28
AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 bi...
12-12 22:49
Academy Sports and Outdoors, Tronox, STAAR Surgical And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining more than 100 points on Tue...
12-10 01:00
Ceribell, Inc. Gains FDA Clearance for Delirium Device
An update from Ceribell, Inc. ( ($CBLL) ) is now available. On December 9, 2025...
12-09 22:50
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
Ceribell's FDA-cleared delirium monitoring solution, the first of its kind, uses EEG and AI to detect delirium in critically ill patients, enabling continuous, objective monitoring. The company's system addresses the gap in early detection and management of delirium, associated with poor outcomes, and enhances clinical decision-making.
12-09 13:00
CeriBell's Clarity Algorithm Gets FDA's Clearance To Detect Electrographic Seizures In Newborns Pre-Term, Older
CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug
11-24 21:03
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Ceribell, Inc. announced FDA clearance for its Clarity algorithm to detect seizures in pre-term neonates through adults, making the Ceribell System the first AI-powered point-of-care EEG technology for this purpose. This addresses a critical need in neonatal care, where up to 90% of seizures go undetected without EEG monitoring, improving timely diagnosis and treatment to reduce brain injury risks.
11-24 13:00
